Diagnostic Testing and Emerging Technologies- G2 Intelligence

AI in Health Care: Balancing Benefits and Barriers

By Michael Schubert, PhD | Oct 30, 2024 | 1 min read

AI can help alleviate the burden on clinical labs—but only with sufficient investment, enthusiasm, and understanding

Background photo showing medical record changing from paperwork to electronic medical record.

Esophageal Pre-Cancer Testing Gaining Greater Traction

By Ron Shinkman | Oct 29, 2024 | 1 min read

How three companies are addressing screening challenges with tests that help improve chances of early detection

An elderly male patient holds a hand to his throat as he speaks with his doctor, illustrating the concept of throat problems and potential esophageal cancer.

Computing the Future of the Lab

By Michael Schubert, PhD | Oct 28, 2024 | 1 min read

Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab

neuron 3D illustration, illustrating convolutional neural networks concept.

Zika Antibody Detection Tests Go from Emergency to Commercial Clearance

By Glenn S. Demby | Nov 16, 2019 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Test Utilization: ‘Cascades of Care’ Cause Wasteful, Unnecessary and Anxiety-Producing Testing

By Glenn S. Demby | Nov 16, 2019 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Emerging Tests: New Genetic Tests May Be Better than PSA Screening in Assessing Prostate Cancer Risk

By Glenn S. Demby | Nov 16, 2019 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Kellison and G2 Intelligence Honor Dr. Sidney Goldblatt

By Glenn S. Demby | Nov 13, 2019 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

Emerging Tests: FDA Issues New Guidance on Using NGS Data to Secure Antiviral Drug & CDx Test Approval

By Glenn S. Demby | Oct 17, 2019 | 1 min read

...

This content is for Paid Members only.
Register

Already a member? Log in here

FDA Watch: Expanded Label Clearance Opens Cologuard to a Younger Market

By Glenn S. Demby | Oct 17, 2019 | 1 min read

September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.